Cargando…

Altered DNA Methylation Profiles in SF3B1 Mutated CLL Patients

Mutations in splicing factor genes have a severe impact on the survival of cancer patients. Splicing factor 3b subunit 1 (SF3B1) is one of the most frequently mutated genes in chronic lymphocytic leukemia (CLL); patients carrying these mutations have a poor prognosis. Since the splicing machinery an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pacholewska, Alicja, Grimm, Christina, Herling, Carmen D., Lienhard, Matthias, Königs, Anja, Timmermann, Bernd, Altmüller, Janine, Mücke, Oliver, Reinhardt, Hans Christian, Plass, Christoph, Herwig, Ralf, Hallek, Michael, Schweiger, Michal R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8431484/ https://www.ncbi.nlm.nih.gov/pubmed/34502260 http://dx.doi.org/10.3390/ijms22179337

Ejemplares similares

QSEA—modelling of genome-wide DNA methylation from sequencing enrichment experiments
por: Lienhard, Matthias, et al.
Publicado: (2017)

Evaluation of a Prognostic Epigenetic Classification System in Chronic Lymphocytic Leukemia Patients
por: Grimm, Christina, et al.
Publicado: (2022)

Obinutuzumab in Allogeneic Transplantation for CLL and Richter’s Transformation in the Age of Targeted Therapies
por: Pflug, Natali, et al.
Publicado: (2021)

DNA–Methylome Analysis of Mouse Intestinal Adenoma Identifies a Tumour-Specific Signature That Is Partly Conserved in Human Colon Cancer
por: Grimm, Christina, et al.
Publicado: (2013)

Minimal Residual Disease Assessment in CLL: Ready for Use in Clinical Routine?
por: Fürstenau, Moritz, et al.
Publicado: (2019)

Micro-RNA networks in T-cell prolymphocytic leukemia reflect T-cell activation and shape DNA damage response and survival pathways
por: Braun, Till, et al.
Publicado: (2020)

IsoTools: a flexible workflow for long-read transcriptome sequencing analysis
por: Lienhard, Matthias, et al.
Publicado: (2023)

Epigenomic profiling of non-small cell lung cancer xenografts uncover LRP12 DNA methylation as predictive biomarker for carboplatin resistance
por: Grasse, Sabrina, et al.
Publicado: (2018)

Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab
por: Freeman, C L, et al.
Publicado: (2016)

MEDIPS: genome-wide differential coverage analysis of sequencing data derived from DNA enrichment experiments
por: Lienhard, Matthias, et al.
Publicado: (2014)

Methylome-based cell-of-origin modeling (Methyl-COOM) identifies aberrant expression of immune regulatory molecules in CLL
por: Wierzbinska, Justyna A., et al.
Publicado: (2020)

Machine learning can identify newly diagnosed patients with CLL at high risk of infection
por: Agius, Rudi, et al.
Publicado: (2020)

Targeting ATM-deficient CLL through interference with DNA repair pathways
por: Knittel, Gero, et al.
Publicado: (2015)

Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial
por: von Tresckow, Julia, et al.
Publicado: (2022)

Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies
por: Thomalla, D., et al.
Publicado: (2022)

Mutations driving CLL and their evolution in progression and relapse
por: Landau, Dan A., et al.
Publicado: (2015)

CLL-033 Is COVID-19 Infection a Trigger for Progression of CLL?
por: Popov, Viola, et al.
Publicado: (2022)

Targeted high throughput sequencing in clinical cancer Settings: formaldehyde fixed-paraffin embedded (FFPE) tumor tissues, input amount and tumor heterogeneity
por: Kerick, Martin, et al.
Publicado: (2011)

Leptomeningeal involvement in CLL
por: Chantepie, Sylvain P., et al.
Publicado: (2014)

Not all lymphoid aggregates in chronic lymphocytic leukemia (CLL) patients are due to CLL!
por: Mahapatra, Lily, et al.
Publicado: (2021)

Poster: CLL-033 Is COVID-19 Infection a Trigger for Progression of CLL?
por: Popov, Viola, et al.
Publicado: (2022)

CLL-461 Humoral Response to COVID-19 Vaccine: A Challenge in CLL
por: Capasso, Antonella, et al.
Publicado: (2022)

CLL-IPI applied in Binet A CLL: a nationwide cohort study
por: Rotbain, Emelie C., et al.
Publicado: (2022)

Differential Expression of Serum MicroRNAs Supports CD4(+) T Cell Differentiation into Th2/Th17 Cells in Severe Equine Asthma
por: Pacholewska, Alicja, et al.
Publicado: (2017)

Poster: CLL-461 Humoral Response to COVID-19 Vaccine: A Challenge in CLL
por: Capasso, Antonella, et al.
Publicado: (2022)

The Mysterious Actor—γδ T Lymphocytes in Chronic Lymphocytic Leukaemia (CLL)
por: Zarobkiewicz, Michał K., et al.
Publicado: (2022)

Significance of t (8: 14) in CLL?
por: Lakshmaiah, K. C., et al.
Publicado: (2010)

CLL kinetics in the tumor microenvironment
por: Sun, Clare, et al.
Publicado: (2017)

Tumor suppressors revival in CLL
por: Carrà, Giovanna, et al.
Publicado: (2017)

CLL und Covid-19
por: Behrend, Christian
Publicado: (2022)

Current Treatment Options in CLL
por: Bewarder, Moritz, et al.
Publicado: (2021)

PB1952: CLL IN AYA
por: Mohamed, Shehab, et al.
Publicado: (2023)

COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study
por: Chatzikonstantinou, Thomas, et al.
Publicado: (2021)

LPS-induced modules of co-expressed genes in equine peripheral blood mononuclear cells
por: Pacholewska, Alicja, et al.
Publicado: (2017)

Differences in miRNA differential expression in whole blood between horses with sarcoid regression and progression
por: Unger, Lucia, et al.
Publicado: (2018)

Optimized methods for extracting circulating small RNAs from long-term stored equine samples
por: Unger, Lucia, et al.
Publicado: (2016)

COVID-19 among fit patients with CLL treated with venetoclax-based combinations
por: Fürstenau, Moritz, et al.
Publicado: (2020)

P630: SAFETY AND TREATMENT ADHERENCE WITH ACALABRUTINIB IN VERY OLD (≥80Y) AND/OR FRAIL PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) - INTERIM SAFETY ANALYSIS OF THE ONGOING PHASE-II CLL-FRAIL TRIAL
por: Simon, Florian, et al.
Publicado: (2023)

S200: IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT-NAÏVE EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FINAL RESULTS OF THE PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED CLL12 TRIAL
por: Langerbeins, Petra, et al.
Publicado: (2023)

Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab
por: Fink, A M, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_s57qur2h2bmv49ne31l08n7fmj